Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent drug formulations, operating within the healthcare and biopharmaceutical sector. The company filed a Form 10-Q with the SEC on November 7, 2018, providing quarterly financial disclosures as a public reporting entity. Ensysce subsequently became the target of a de-SPAC business combination with Leisure Acquisition Corp, a blank-check company, with the combined entity listing on the Nasdaq Capital Market in 2021 under the ENSC ticker. The company's pipeline centers on proprietary controlled-substance technologies designed to reduce medication misuse. Sign up on SpacDesk for full filing history, sponsor profiles, and deal-level data on ENSC.